Beyond Air Targets $1 Billion Market with Gen 2 LungFit Platform

Key Facts

1Beyond Air aims to secure FDA approval for its Generation 2 LungFit nitric oxide platform by the end of 2026.

2The company projects that its Generation 2 products will expand its global addressable market to $1 billion.

3The company reiterated 2026 revenue guidance of $8 million, with projections reaching up to $18 million in 2027.

In a move reflecting strategic expansion within the medical device sector, Beyond Air is prioritizing the development of its Generation 2 LungFit platform. The company aims to secure U.S. FDA approval for this next-generation nitric oxide system by the end of 2026. According to reports, this platform is critical for patient transport settings, which is expected to significantly broaden the company's operational scope and market reach.

The company projects that its Generation 2 products will expand its global addressable market to approximately $1 billion. Consequently, Beyond Air has reiterated its revenue guidance for 2026 at $8 million, with projections climbing to $18 million by 2027. This growth trajectory is centered on leveraging the new platform to capture a larger share of the specialized respiratory care market.

The stock, XAIR, stood at $3.07 at the close of September 10, 2026, after trading within a daily range of $3.06 to $3.19. Investors should monitor upcoming regulatory milestones as catalysts for the stock. Meanwhile, broader market sentiment has been influenced by recent data such as Germany's Industrial Production, which fell by 1.1% on September 7, 2026, reflecting ongoing volatility in global manufacturing environments.